Dr. Reddy's Laboratories Ltd Common Stock (RDY)

FairStock Score: 54/100 — MIXED

Key Financials

Strengths

• Generates $13.5 billion in annual free cash flow (118.3% yield on market cap)
• Solid return on equity of 16.1% above cost of capital
• Conservative balance sheet with debt-to-equity of just 0.18, providing financial flexibility
• Established organization with 27,811 employees providing operational scale

Concerns

• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions
• Altman Z-Score of 1.4 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Dr. Reddy's Laboratories Ltd Common Stock is a mid-cap healthcare company valued at $11.4 billion. The business generates $345.8 billion in annual revenue with a 3.5% net margin and $13.5 billion in free cash flow. From a quality standpoint, Dr. shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and distressed Altman Z-Score of 1.4 warrants caution. On valuation, the stock is reasonably priced at 18.6x earnings, with offers a 84% margin of safety vs Graham Number of $86. Growth dynamics show revenue growing at 4.4% and profit growth of -14.4%. Our composite FairStock Score of 54/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $13.5 billion in annual free cash flow (118.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Sluggish 4% growth in a large-cap company leaves the stock vulnerable to de-rating if the market rotates toward higher-growth opportunities.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer